Clinical Trials

Breast Neoplasms

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

30 enrolled

Phase NA Active not recruiting

Triple Negative Breast Neoplasms

NCT01928589 2026-03-06

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

81 enrolled

Breast Neoplasms

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Phase 3 Recruiting

318 enrolled

Triple Negative Breast Neoplasms

NCT07372079 2026-01-28

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

40 enrolled

Breast Neoplasms

NCT05909332 2026-01-21

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Phase 3 Recruiting

764 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT06596018 2025-12-30

Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy

Phase 1/2 Recruiting

96 enrolled

Breast Neoplasms

NCT02806258 2025-12-29

Néo-APBI-01

Phase 1/2 Terminated

362 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00929214 2025-12-17

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

35 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

120 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05076682 2025-12-03

Renaissance

80 enrolled

Triple Negative Breast Neoplasms

NCT06731140 2025-11-17

Resilire

10 enrolled

Phase NA Not yet recruiting

HER2 Negative Breast Cancer

NCT07187752 2025-09-23

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

1,039 enrolled

Breast Neoplasms

NCT03283384 2025-09-19

NEOLBC

100 enrolled

BreastGastrointestinalLymphoidPlasma cell

Breast Neoplasms

NCT07152938 2025-09-15

AVR-CHEMO

Phase NA Completed

150 enrolled

Agnosia, Anxiety Disorders, Breast Neoplasms, Colonic Neoplasms, Lymphoma, Multiple Myeloma, Neoplasms

NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Phase 1/2 Not yet recruiting

12 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07137793 2025-08-22

PTX / BC

46 enrolled

Breast Neoplasms

NCT07108309 2025-08-07

AREAL

124 enrolled

Triple Negative Breast Neoplasms

NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

30 enrolled

Triple Negative Breast Neoplasms

NCT07101614 2025-08-03

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

125 enrolled

Phase NA Active not recruiting

Triple Negative Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

798 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

25 enrolled

Triple Negative Breast Neoplasms

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Phase 2 Completed

10 enrolled

HER2-negative Metastatic Breast Cancer

NCT06678048 2025-06-06

Arsenous Acid for Refractory Triple-Negative Breast Cancer

12 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07005557 2025-06-05

SENIOR

1,244 enrolled

Phase NA Active not recruiting

Breast Neoplasms

NCT06190600 2025-04-30

SPORTNATHy

40 enrolled

Breast Neoplasms, Motor Activity

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

20 enrolled

Triple Negative Breast Neoplasms

NCT06642441 2025-01-17

Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer

Phase NA Recruiting

100 enrolled

Breast Neoplasms

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

148 enrolled

BreastThoracic

NSCLC

NCT06727357 2024-12-10

Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP

38 enrolled

Breast Neoplasms

NCT03227328 2024-11-07

KENDO

Phase 2 Completed

52 enrolled

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

130 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Patient Acceptance of Health Care

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

200 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06438055 2024-05-31

Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

Phase NA Not yet recruiting

40 enrolled

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

Phase 2 Completed

73 enrolled

Breast Neoplasms

NCT06341621 2024-04-10

Rainbow

Phase 3 Recruiting

1,900 enrolled